Adagene partners with Incyte for cancer drug combination study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: ADAG) | Delayed: 2.44 +0.03 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.41 | 52 Week High | $ | |||
| Open | $2.24 | 52 Week Low | $ | |||
| Day High | $2.51 | P/E | N/A | |||
| Day Low | $2.24 | EPS | $ | |||
| Volume | 244,221 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.93 +3.49 (3.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.44 | 52 Week High | $118.49 | |||
| Open | $113.93 | 52 Week Low | $55.00 | |||
| Day High | $117.17 | P/E | N/A | |||
| Day Low | $112.76 | EPS | $-0.56 | |||
| Volume | 2,235,284 | |||||
